Pharmacology of Nonsteroidal Antiinflammatory Drugs and Opioids

Dick Slater; Sushama Kunnathil; Joseph McBride; Rajah Koppala

doi:10.1055/s-0030-1267855

Seminars in Interventional Radiology, Table of Contents

Semin intervent Radiol 2010; 27(4): 400-411
DOI: 10.1055/s-0030-1267855

Pharmacology of Nonsteroidal Antiinflammatory Drugs and Opioids

Dick Slater¹ , Sushama Kunnathil¹ , Joseph McBride¹ , Rajah Koppala¹

¹Department of Radiology, University of Nebraska Medical Center, Omaha, Nebraska

Abstract

ABSTRACT

Chronic pain affects up to 50 million Americans every day. Traditional treatment has included acetaminophen, nonsteroidal antiinflammatory drugs (NSAIDs), or opioids. The combination of NSAIDs and opioids can provide effective treatment for up to 90% of patients with chronic pain, but the NSAIDs have the potential for significant, even life-threatening side effects. Additionally, the nonselective cyclooxygenase inhibitors with 16,000 deaths per year in the United States might not be any safer. The opioids are great for short-term pain, but may need to be adjusted or changed frequently due to the development of tolerance. Understanding of the mechanism of opioids and NSAIDs has improved greatly over the past decade, but is still incomplete.

KEYWORDS

NSAIDs - opioids - analgesics - mechanisms - pharmacology

Full Text

References

REFERENCES

1 Dubois M Y, Gallagher R M, Lippe P M. Pain medicine position paper. Pain Med. 2009; 10(6) 972-1000
2 Breivik H, Cherny N, Collett B et al.. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009; 20(8) 1420-1433 , 10.1093/annonc/mdp001
3 Tauberer J. A civic project to track Congress. Available at: http://www.govtrack.us/congress/bill.xpd?bill=h111-756&tab=committees Accessed October 3, 2009
4 Ueberall M, Mueller-Schwefe G. 705 individual treatment targets in chronic pain management. Eur J Pain. 2006; 10 S184
5 Abeles A M, Pillinger M H, Solitar B M, Abeles M. Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med. 2007; 146(10) 726-734
6 Merskey H, Bogduk N Pain 1. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. 2nd ed. Seattle; IASP Press 1994: 209-214
7 Fields R D. New culprits in chronic pain. Sci Am. 2009; 301(5) 50-57
8 Woodcock J, Witter J, Dionne R A. Stimulating the development of mechanism-based, individualized pain therapies. Nat Rev Drug Discov. 2007; 6(9) 703-710
9 Levy M H. Pharmacologic treatment of cancer pain. N Engl J Med. 1996; 335(15) 1124-1132
10 Smyth E M, FitzGerald G A. The eicosanoids: prostaglandins, thromboxanes, leukotrienes, and related compounds. In: Katzung BG, Masters SB, Trevor AJ Basic & Clinical Pharmacology. 11th ed. New York; McGraw-Hill 2009: 313-330
11 Yaksh T L, Dirig D M, Malmberg A B. Mechanism of action of nonsteroidal anti-inflammatory drugs. Cancer Invest. 1998; 16(7) 509-527
12 Wallace J L, Cirino G. The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci. 1994; 15(11) 405-406
13 Wallace J L. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?. Physiol Rev. 2008; 88(4) 1547-1565
14 Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 1998; 105(1B, 1B) 31S-38S
15 Lockrey G J. Management of peptic ulcer disease in older people. Aust J Hosp Pharm. 1999; 29 45-50
16 Gislason G H, Jacobsen S, Rasmussen J N et al.. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006; 113(25) 2906-2913
17 Jensen B L, Kurtz A. Differential regulation of renal cyclooxygenase mRNA by dietary salt intake. Kidney Int. 1997; 52(5) 1242-1249
18 Kömhoff M, Grone H J, Klein T, Seyberth H W, Nüsing R M. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol. 1997; 272(4 Pt 2) F460-F468
19 Silbernagl S, Lang F. Color Atlas of Pathophysiology. Stuttgart and New York; Thieme Medical Publishing 2000: 118
20 Sankaran D, Bankovic-Calic N, Ogborn M R, Crow G, Aukema H M. Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease. Am J Physiol Renal Physiol. 2007; 293(3) F821-F830
21 Hao C M, Breyer M D. Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol. 2008; 70 357-377
22 Sankaran D, Bankovic-Calic N, Ogborn M R, Crow G, Aukema H M. Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease. Am J Physiol Renal Physiol. 2007; 293(3) F821-F830
23 David Josephy P. The molecular toxicology of acetaminophen. Drug Metab Rev. 2005; 37(4) 581-594 , 10.1080/03602530500205200
24 Anderson B J. Paracetamol (acetaminophen): mechanisms of action. Paediatr Anaesth. 2008; 18(10) 915-921
25 Davies N M, Good R L, Roupe K A, Yáñez J A. Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error?—Not as easy as 1, 2, 3. J Pharm Pharm Sci. 2004; 7(2) 217-226
26 Chandrasekharan N V, Dai H, Roos K L et al.. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002; 99(21) 13926-13931 , [PMID: 12242329]
27 Mackowiak P A. Brief history of antipyretic therapy. Clin Infect Dis. 2000; 31(Suppl 5) S154-S156
28 Furst D, Ulrich R, Varkey-Altamirano C. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics, & drugs used in gout. In: Katzung BG, Masters SB, Trevor AJ Basic & Clinical Pharmacology. 11th ed. New York; McGraw-Hill 2009: 621-642
29 Pearson T A, Blair S N, Daniels S R American Heart Association Science Advisory and Coordinating Committee et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. Circulation. 2002; 106(3) 388-391
30 Giovannucci E, Rimm E B, Stampfer M J, Colditz G A, Ascherio A, Willett W C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994; 121(4) 241-246
31 Glasgow J F. Reye's syndrome: the case for a causal link with aspirin. Drug Saf. 2006; 29(12) 1111-1121
32 Hawkey C J, Karrasch J A, Szczepañski L et al.. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998; 338(11) 727-734
33 Stillman M J, Stillman M T. Choosing nonselective NSAIDs and selective COX-2 inhibitors in the elderly. A clinical use pathway. Geriatrics. 2007; 62(2) 26-34
34 Przewlocki R, Przewlocka B. Opioids in neuropathic pain. Curr Pharm Des. 2005; 11(23) 3013-3025
35 Busch-Dienstfertig M, Stein C. Opioid receptors and opioid peptide-producing leukocytes in inflammatory pain—basic and therapeutic aspects. Brain Behav Immun. 2010; 24(5) 683-694
36 Stein C, Lang L J. Peripheral mechanisms of opioid analgesia. Curr Opin Pharmacol. 2009; 9(1, Issue 1) 3-8
37 O'Connor A B, Dworkin R H. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009; 122(10, Suppl) S22-S32
38 Evans R M, You H, Hameed S et al.. Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium channel regulation. J Biol Chem. 2010; 285(2) 1032-1040
39 Marker C L, Luján R, Loh H H, Wickman K. Spinal G-protein-gated potassium channels contribute in a dose-dependent manner to the analgesic effect of mu- and delta- but not kappa-opioids. J Neurosci. 2005; 25(14) 3551-3559
40 Eippert F, Bingel U, Schoell E D et al.. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron. 2009; 63(4) 533-543
41 Cox B M, Chavkin C, Christie M J et al.. Opioid receptors. In: The IUPHAR Compendium of Receptor Characterization and Classification. London; IUPHAR Media Ltd. 2000: 321-333
42 Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept. 2009; 155(1-3) 11-17
43 Corbett A D, Henderson G, McKnight A T, Paterson S J. 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol. 2006; 147(Suppl 1) S153-S162 , 10.1038/sj.bjp.0706435 PMID 16402099
44 Aggrawal A. Opium: the king of narcotics. In: Aggrawal A Narcotic Drugs. New Delhi; New Delhi National Book Trust 1995: 161
45 Ackley M A, Baldwin S A, King A E. Adenosine contributes to mu-opioid synaptic inhibition in rat substantia gelatinosa in vitro. Neurosci Lett. 2005; 376(2) 102-106
46 Walsh S L, Chausmer A E, Strain E C, Bigelow G E. Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacology (Berl). 2008; 196(1) 143-155
47 Bodnar R J. Endogenous opiates and behavior. Peptides. 2009; 30(12) 2432-2479 , doi:10.1016/j.peptides.2009.09.027
48 Abramow-Newerly M, Roy A A, Nunn C, Chidiac P. RGS proteins have a signalling complex: interactions between RGS proteins and GPCRs, effectors, and auxiliary proteins. Cell Signal. 2006; 18(5) 579-591
49 Khafizov K, Lattanzi G, Carloni P. G protein inactive and active forms investigated by simulation methods. Proteins. 2009; 75(4) 919-930
50 Pravetoni M, Wickman K. G protein gated potassium channels (GIRK/ Kir3) mediate the motor stimulatory effects of opiates. FASEB J. 2008; 22 712
51 Mao J. Opioid-induced abnormal pain sensitivity. Curr Pain Headache Rep. 2006; 10(1) 67-70
52 Angst M S, Clark J D. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006; 104(3) 570-587
53 Angst M S, Koppert W, Pahl I, Clark D J, Schmelz M. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain. 2003; 106(1-2) 49-57
54 Lewis S S, Hutchinson M R, Rezvani N et al.. Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta. Neuroscience. 2010; 165(2) 569-583
55 Ballantyne J C, Shin N S. Efficacy of opioids for chronic pain: a review of the evidence. Clin J Pain. 2008; 24(6) 469-478
56 Price D D, Mayer D J, Mao J et al.. NMDA-receptor antagonists and opioid receptor interactions as related to analgesia and tolerance. J Pain Symptom Manage. 2000; 19(1, Suppl) 7-11
57 Leppert W. The role of methadone in opioid rotation-a Polish experience. Support Care Cancer. 2009; 17(5) 607-612
58 Vadalouca A, Moka E, Argyra E, Sikioti P, Siafaka I. Opioid rotation in patients with cancer: a review of the current literature. J Opioid Manag. 2008; 4(4) 213-250
59 Thomas J, Karver S, Cooney G A et al.. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008; 358(22) 2332-2343
60 Holzer P. New approaches to the treatment of opioid-induced constipation. Eur Rev Med Pharmacol Sci. 2008; 12(Suppl 1) 119-127
61 Wang J J, Ho S T, Tzeng J I. Comparison of intravenous nalbuphine infusion versus naloxone in the prevention of epidural morphine-related side effects. Reg Anesth Pain Med. 1998; 23(5) 479-484
62 Roberts L, Finch P, Pullan P et al.. Sex hormone suppression by intrathecal opioids: a prospective study. Clin J Pain. 2002; 8(3) 144-148
63 Smith H S. Opioid metabolism. Mayo Clin Proc. 2009; 84(7) 613-624
64 Foster A, Mobley E, Wang Z. Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Pract. 2007; 7(4) 352-356
65 Raffa R. Pharmacological aspects of successful long-term analgesia. Clin Rheumatol. 2006; 25(Suppl 1) S9-S15 , 10.1007/s10067-006-0201-x
66 de Leon-Casasola O A, Lema M J. Postoperative epidural opioid analgesia: what are the choices?. Anesth Analg. 1996; 83(4) 867-875
67 Manfredi P L, Houde R W. Prescribing methadone, a unique analgesic. J Support Oncol. 2003; 1(3) 216-220
68 Varvel J R, Shafer S L, Hwang S S, Coen P A, Stanski D R. Absorption characteristics of transdermally administered fentanyl. Anesthesiology. 1989; 70(6) 928-934
69 Hutchison L, O'Brien C E. Changes in pharmacokinetics and pharmacodynamics in the elderly patient. J Pharm Pract. 2007; 20(1) 4-12
70 Fallon M, Hanks G, Cherny N. Principles of control of cancer pain. BMJ. 2006; 332(7548) 1022-1024
71 Lussier D, Huskey A G, Portenoy R K. Adjuvant analgesics in cancer pain management. Oncologist. 2004; 9(5) 571-591 , 10.1634/theoncologist.9-5-57
72 PharmacyChecker.com LLC .Compare drug prices. http://Available at: http: www.pharmacychecker.com Accessed October 10, 2009

Dick SlaterM.D.

Department of Radiology, University of Nebraska Medical Center

4200 Emile, Omaha, NE 68198

Email: Dslater@unmc.edu